Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Conditions
Keywords
Locally Advanced, Metastatic
Brief summary
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.
Detailed description
This first-in-human study of SBP-101 will be conducted in two phases: dose escalation and expansion. The dose escalation phase of the study is to evaluate the safety, tolerability and PK profile of SBP-101 in subjects with previously treated locally advanced or metastatic pancreatic ductal adenocarcinoma. Up to 48 subjects may be enrolled in dose escalation. The expansion phase of the study will consist of 24 additional subjects who will receive the maximum tolerated dose of SBP-101 based on data from the dose escalation phase of the study.
Interventions
DRUGSBP-101
Subcutaneous drug, escalating dose cohorts
Sponsors
Panbela Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with acinar cell carcinoma may also be included. * Measurable disease on CT or MRI scan by RECIST criteria (required for Phase 1b only). * ECOG Performance Status 0 or 1. * Received and failed, or were intolerant to, at least 1 prior systemic therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma. * Adult, at least 18 years of age, male or female * Females of child-bearing potential must have a negative serum pregnancy test within 14 days prior to start of study treatment and must use an adequate method of contraception during the study. All sexually active males must also use an adequate method of contraception during the study. * Adequate bone marrow, hepatic, renal and coagulation function as defined by the following: Absolute neutrophil count ≥1.5 x 10\^9/L, Hemoglobin ≥9.0 g/dL (90 g/L), Platelets ≥100 x 10\^9/L, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement, AST and ALT ≤5 x ULN, Bilirubin ≤1.5 x ULN, Prothrombin time (PT) / international normalized ratio (INR) ≤1.5 x ULN, Calculated creatinine clearance \>50 mL/min using the Cockcroft and Gault equation * QTc interval ≤ 470 msec at Baseline * Willing and able to provide written informed consent: voluntary agreement to participate in the study following disclosure of risks and procedures required, including possibility of onset of exocrine pancreatic insufficiency with subsequent requirement for life-long pancreatic enzyme replacement
Exclusion criteria
* Evidence of severe or uncontrolled systemic disease or any concurrent condition that, in the opinion of the Investigator or Medical Monitor, makes it undesirable for the subject to participate in the study or that would jeopardize compliance with the protocol. Subjects with pre-existing well-controlled diabetes are not excluded. * Medical or psychiatric conditions that compromise the subject's ability to give informed consent or to complete the protocol or a history of non-compliance * Presence of islet-cell or pancreatic neuroendocrine tumor or mixed adenocarcinoma-neuroendocrine carcinoma * Have symptomatic central nervous system (CNS) malignancy or metastasis. Screening of asymptomatic subjects without history of CNS metastases is not required. * Serum albumin \<30 g/L (3.0 g/dL) * Glycosylated hemoglobin (Hgb A1C) \> 8.0% * Life expectancy \<16 weeks * Presence of known active bacterial, fungal, or viral infection requiring systemic therapy * Known infection with human immunodeficiency virus (HIV), hepatitis B or C * Presence of interstitial lung disease, pulmonary fibrosis, or pulmonary hypersensitivity reaction * Myocardial infarction within the last 12 months, severe/unstable angina, symptomatic congestive heart failure, New York Heart Association (NYHA) class III or IV * Maldigestion/malabsorption syndrome pre-dating the diagnosis of pancreatic cancer. * Known, existing coagulopathy or receiving anticoagulants * Pregnant or lactating * Major surgery within 4 weeks of the start of study treatment, without complete recovery * Participation in any other clinical investigation within 4 weeks of receiving the first dose of study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose of SBP-101 | Up to 18 months following the first dose of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Number of subjects with adverse events as a measure of safety and tolerability | Up to 30 months following the first dose of treatment |
| Tumor response will be evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) definitions | Every 8 weeks during treatment assessed up to 30 months |
| Area under the plasma concentration versus time curve (AUC) | Days 1 and 18 of Cycle 1 (each cycle is 8 weeks) |
| Peak plasma concentration (Cmax) | Days 1 and 18 of Cycle 1 (each cycle is 8 weeks) |
| Plasma drug half-life | Days 1 and 18 of Cycle 1 (each cycle is 8 weeks) |
Countries
Australia, United States
Outcome results
None listed